Boston Life Sciences Provides Further Description and Clarification of Recent Experimental Stroke Study.

Business Editors & Health/Medical Writers

BIOWIRE2K

BOSTON--(BW HealthWire)--Sept. 8, 2000

Boston Life Sciences, Inc. (NASDAQ: BLSI) provided further details of a recently completed stroke model in rats, whereby a 28-day infusion (following the stroke) of Inosine directly in the Cerebral Spinal Fluid (CSF), resulted in substantial recovery of limb movement in treated animals as compared to controls.

In this study, the middle cerebral artery was occluded, resulting in an anatomically well-characterized cerebral infarct with hemi-paresis (weakness) of the fore and hindlimb on the opposite side. A catheter was immediately placed into the CSF at the level of the cisterna magna at the base of the brain and connected to a subcutaneously placed mini-pump loaded with Inosine. Inosine was then infused at a constant rate of 2.5 ul/hr for 28 days. It is estimated that effective, steady state Inosine concentrations in the CSF were reached approximately 1-2 days after infarct. Limb function was assessed in a blinded manner at bi-weekly intervals after the stroke. Such functional improvement in treated animals was highly statistically significant compared to control animals, which continued to exhibit severe impairments. After the 28-day infusion, the brains were removed and preserved for future histological analysis. A complete description of the methodology and data related to this experiment will be provided in a manuscript to be submitted to a peer-reviewed journal.

BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease (PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune disease, and central nervous system disorders. BLSI's products in development include: Altropane, a radioimaging agent for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine, nerve growth factors for the treatment of acute and chronic CNS disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies.

Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, the outcome of discussions with potential partners, regulatory decisions, market acceptance of the Company's products, and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K.